This Guidance for country COVID-19 after action review (AAR) aims to support countries in achieving this recommendation to systematically review their respective responses to COVID-19. It provides step-by-step instructions and relevant tools to conduct a country COVID-19 AAR.
Many vaccines and drugs hold the promise of reducing mortality and morbidity among pregnant women and infants living in low- and middle-income countries (LMICs). However, sufficient information on the safety of drugs and vaccines in pregnant women is rarely available at the time of product licensure or approval.